Veozah (fezolinetant) is a non-hormonal medication approved for treating moderate to severe vasomotor symptoms (hot flashes) associated with menopause. Common side effects include abdominal pain, diarrhea, insomnia, back pain, and hot flashes or hot flushes. A significant concern is the potential for rare but serious liver injury, prompting the FDA to require liver function tests before starting treatment and at months 3, 6, and 9 during therapy. Signs of liver problems may include fatigue, nausea, vomiting, itching, yellowing of the skin or eyes (jaundice), pale stools, dark urine, and upper abdominal pain. Patients experiencing these symptoms should stop taking Veozah and contact their healthcare provider immediately. Due to these risks, Veozah is not recommended for individuals with cirrhosis, severe kidney issues, or those taking certain CYP1A2 inhibitors.